OTCMKTS:EPRSQ

EPIRUS Biopharmaceuticals Competitors

$0.02
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.02
$0.03
52-Week Range
$0.00
Now: $0.02
$0.24
Volume113,076 shs
Average Volume132,482 shs
Market Capitalization$374,233.00
P/E RatioN/A
Dividend YieldN/A
Beta6.03

Competitors

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Vs. AKAOQ, COTQF, TLOG, AOXG, PPCB, and ANTH

Should you be buying EPRSQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to EPIRUS Biopharmaceuticals, including Achaogen (AKAOQ), Cotinga Pharmaceuticals (COTQF), TetraLogic Pharmaceuticals (TLOG), Aoxing Pharmaceutical (AOXG), Propanc Biopharma (PPCB), and Anthera Pharmaceuticals (ANTH).

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for EPIRUS Biopharmaceuticals and Achaogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
EPIRUS Biopharmaceuticals0000N/A
Achaogen0000N/A

Earnings & Valuation

This table compares EPIRUS Biopharmaceuticals and Achaogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A
Achaogen$8.73 million0.15$-186,510,000.00N/AN/A

EPIRUS Biopharmaceuticals has higher earnings, but lower revenue than Achaogen.

Risk & Volatility

EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its stock price is 503% more volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500.

Insider and Institutional Ownership

0.0% of Achaogen shares are owned by institutional investors. 13.1% of EPIRUS Biopharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares EPIRUS Biopharmaceuticals and Achaogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EPIRUS BiopharmaceuticalsN/AN/AN/A
AchaogenN/AN/AN/A

Cotinga Pharmaceuticals (OTCMKTS:COTQF) and EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Volatility & Risk

Cotinga Pharmaceuticals has a beta of 43.44, meaning that its stock price is 4,244% more volatile than the S&P 500. Comparatively, EPIRUS Biopharmaceuticals has a beta of 6.03, meaning that its stock price is 503% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cotinga Pharmaceuticals and EPIRUS Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Cotinga Pharmaceuticals and EPIRUS Biopharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cotinga Pharmaceuticals0000N/A
EPIRUS Biopharmaceuticals0000N/A

Profitability

This table compares Cotinga Pharmaceuticals and EPIRUS Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cotinga PharmaceuticalsN/AN/AN/A
EPIRUS BiopharmaceuticalsN/AN/AN/A

Summary

Cotinga Pharmaceuticals beats EPIRUS Biopharmaceuticals on 1 of the 1 factors compared between the two stocks.

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for EPIRUS Biopharmaceuticals and TetraLogic Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
EPIRUS Biopharmaceuticals0000N/A
TetraLogic Pharmaceuticals0000N/A

Valuation and Earnings

This table compares EPIRUS Biopharmaceuticals and TetraLogic Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A

Volatility & Risk

EPIRUS Biopharmaceuticals has a beta of 6.03, meaning that its stock price is 503% more volatile than the S&P 500. Comparatively, TetraLogic Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Profitability

This table compares EPIRUS Biopharmaceuticals and TetraLogic Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EPIRUS BiopharmaceuticalsN/AN/AN/A
TetraLogic PharmaceuticalsN/AN/AN/A

Summary

EPIRUS Biopharmaceuticals beats TetraLogic Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and Aoxing Pharmaceutical (OTCMKTS:AOXG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Risk and Volatility

EPIRUS Biopharmaceuticals has a beta of 6.03, meaning that its share price is 503% more volatile than the S&P 500. Comparatively, Aoxing Pharmaceutical has a beta of 3.26, meaning that its share price is 226% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for EPIRUS Biopharmaceuticals and Aoxing Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
EPIRUS Biopharmaceuticals0000N/A
Aoxing Pharmaceutical0000N/A

Profitability

This table compares EPIRUS Biopharmaceuticals and Aoxing Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EPIRUS BiopharmaceuticalsN/AN/AN/A
Aoxing PharmaceuticalN/AN/AN/A

Valuation and Earnings

This table compares EPIRUS Biopharmaceuticals and Aoxing Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A
Aoxing PharmaceuticalN/AN/AN/AN/AN/A

Summary

EPIRUS Biopharmaceuticals beats Aoxing Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Propanc Biopharma (OTCMKTS:PPCB) and EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares Propanc Biopharma and EPIRUS Biopharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Propanc BiopharmaN/AN/A$-4,740,000.00N/AN/A
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Propanc Biopharma and EPIRUS Biopharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Propanc Biopharma0000N/A
EPIRUS Biopharmaceuticals0000N/A

Profitability

This table compares Propanc Biopharma and EPIRUS Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Propanc BiopharmaN/AN/A-4,812.81%
EPIRUS BiopharmaceuticalsN/AN/AN/A

Risk and Volatility

Propanc Biopharma has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its stock price is 503% more volatile than the S&P 500.

Summary

EPIRUS Biopharmaceuticals beats Propanc Biopharma on 2 of the 2 factors compared between the two stocks.

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Valuation & Earnings

This table compares EPIRUS Biopharmaceuticals and Anthera Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A
Anthera PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares EPIRUS Biopharmaceuticals and Anthera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EPIRUS BiopharmaceuticalsN/AN/AN/A
Anthera PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for EPIRUS Biopharmaceuticals and Anthera Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
EPIRUS Biopharmaceuticals0000N/A
Anthera Pharmaceuticals0000N/A

Risk and Volatility

EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its share price is 503% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.

Summary

EPIRUS Biopharmaceuticals beats Anthera Pharmaceuticals on 1 of the 1 factors compared between the two stocks.


EPIRUS Biopharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Decrease in Short Interest
News Coverage
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.01flat$1.05 millionN/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22flat$1.03 millionN/A0.00Decrease in Short Interest
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03flat$963,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$928,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08flat$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.02flat$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03flat$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00flat$678,000.00N/A0.00Increase in Short Interest
SKVI
Skinvisible
0.7$0.15flat$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15flat$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17flat$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07flat$378,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00News Coverage
Gap Up
PZRXQ
PhaseRx
0.2$0.03flat$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09flat$124,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02flat$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02flat$9,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.03flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$35.08flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Down
HRBR
Harbor Diversified
0.0$1.16flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00Gap Up
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Decrease in Short Interest
News Coverage
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.07flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.03flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.07flat$0.00$26.09 million0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.